$EVGN News

Evogene Completes First-In-Human Phase 1 Clinical Study Of BMC128, Rationally-Designed Live Bacterial Product Developed By Its Subsidiary, Biomica, In Combination With Nivolumab In Patients With Advanced Solid Tumors

Evogene Reports Early Results for Cancer Therapy Study, Experimental Treatment Meets Safety Goal in First Human Trial

Evogene Ltd. (EVGN) Q1 2026 Earnings Call Transcript

Evogene Ltd. (NASDAQ:EVGN) Q1 Earnings Miss Sends Shares Lower in Pre-Market

Evogene Files Secondary Offering Of 2,446,707 Shares By Selling Shareholder

Evogene Q1 EPS $(0.60) Misses $(0.27) Estimate, Sales $334.000K Miss $350.000K Estimate

Evogene to Present at the 24th Schrödinger European User Group Meeting

Evogene Schedules First Quarter 2026 Financial Results Release

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

Evogene Receives Nasdaq Noncompliance Notification, Gets Time Through Sept. 28 To Regain Compliance

Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock

Evogene Ltd (EVGN) Q4 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue Decline

Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026

Evogene Ltd. Q4 2025 Earnings Call Summary

Evogene Ltd. (EVGN) Q4 2025 Earnings Call Transcript

Evogene Ltd (NASDAQ:EVGN) Reports Q4 Revenue Beat but Wider-Than-Expected Loss, Shares Drop

Evogene: Q4 Earnings Snapshot

Evogene shares are trading lower after the company reported a Q4 EPS miss.

Evogene shares are trading lower after the company reported a Q4 EPS miss.

Evogene Reports Fourth Quarter and Full Year 2025 Financial Results